Compounded Peptides On The Loose: What The Recent PCAC Meeting Means For Industry

The FDA's Pharmacy Compounding Advisory Committee recently voted to recommend six of seven unapproved peptide bulk drug substances for inclusion on the Agency's 503A bulks list, directly contradicting FDA staff recommendations. This significant regulatory shift raises critical questions about pharmaceutical compounding standards, quality control challenges, and the tension between market-driven demand and scientific rigor in peptide regulation.